| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.medicoremediesindia.com / www.medicoremediesindia.net / www.tabletandcapsules.com | |
| Market Cap | 526.12 Cr. | |
| Enterprise Value(EV) | 538.21 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 2.95 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | 107.59 | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 32.54 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | 23.97 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | 13.22 | Calculated using Price: 317.00 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 1.66 Cr. | 16,596,800 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| The company is engaged in manufacturing and selling of pharmaceutical formulation products in India. The company offers formulation pharmacy products including anti-infective, beta lactum, cephalosporin, antimalarial, antiretroviral, and anti-ulcer drugs, as well as antacids; vitamins, haematinics and other supplements and nonsteroidal anti-inflammatory drugs, antihistaminics, anti-diabetics, cardio vascular drugs, diuretics, anti-epileptics, combination drug kits, syrups and creams and gels. | ||
| 1 Day |
|
+0.97% |
| 1 Week |
|
+4.19% |
| 1 Month |
|
-3.03% |
| 3 Month |
|
+62.69% |
| 6 Month |
|
+248.35% |
| 1 Year |
|
+291.36% |
| 2 Year |
|
+1525.64% |
| 5 Year |
|
|
| 10 Year |
|
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 9.23 | 7.14 | 7.97 | 10.47 | 5.67 | 5.72 | 5.61 | 8.31 | 14.02 | |
| Return on Capital Employed (%) | 11.37 | 10.01 | 10.86 | 9.39 | 9.05 | 7.79 | 7.66 | 10.13 | 15.00 | |
| Return on Assets (%) | 2.54 | 2.36 | 2.78 | 3.47 | 2.26 | 2.31 | 2.15 | 3.43 | 6.44 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 9 | 14 | 15 | 16 | 27 | 28 | 30 | 32 | 37 | 40 | |
| Non Curr. Liab. | 1 | 1 | 4 | 11 | 3 | 3 | 5 | 5 | 1 | 3 | |
| Curr. Liab. | 22 | 22 | 26 | 21 | 30 | 45 | 40 | 38 | 38 | 54 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 31 | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 76 | 96 | |
| Non Curr. Assets | 8 | 10 | 9 | 10 | 14 | 17 | 19 | 17 | 18 | 22 | |
| Curr. Assets | 23 | 26 | 37 | 38 | 46 | 59 | 57 | 58 | 59 | 74 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 31 | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 76 | 96 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Net Sales | 34 | 45 | 51 | 67 | 54 | 61 | 98 | 89 | 122 | 121 | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | |
| Total Income | 34 | 45 | 51 | 67 | 55 | 62 | 100 | 91 | 123 | 123 | |
| Total Expenditure | -32 | -43 | -48 | -63 | -50 | -58 | -95 | -86 | -117 | -114 | |
| PBIDT | 2 | 2 | 3 | 4 | 4 | 4 | 5 | 5 | 6 | 9 | |
| Interest | 0 | -1 | -1 | -1 | -1 | -2 | -1 | -1 | -1 | -1 | |
| Depreciation | 0 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -2 | -2 | |
| Taxation | 0 | 0 | 0 | -1 | 0 | -1 | -1 | -1 | -1 | -2 | |
| Exceptional Items | 0 | ||||||||||
| PAT | 0 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 5 | |
| Adjusted EPS | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 2 | 3 | 0 | -4 | -3 | 5 | 5 | 1 | -11 | 2 | |
| Cash Fr. Inv. | -2 | -4 | -2 | 0 | -3 | -5 | -4 | -3 | -17 | -3 | |
| Cash Fr. Finan. | 0 | 2 | 3 | 2 | 6 | -1 | -1 | 3 | 18 | 7 | |
| Net Change | 0 | 1 | 0 | -1 | 0 | -1 | 0 | 0 | -10 | 6 | |
| Cash & Cash Eqvt | 0 | 1 | 2 | 1 | 0 | 0 | 0 | 1 | -10 | 6 |
|
Fri, 13 Jan 2023
Board Meeting Intimation for Announcement Of Board Meeting As Per Regulation 29 Of SEBI (LODR) Regulations 2015 Medico Remedies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/02/2023 inter alia to consider and approve Pursuant to Regulation 29(3) of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday 2nd February 2023 inter alia to consider and approve:1. Sub-division/ Stock Split of equity shares of the Company.2. Any other matter with the permission of the Chair. |
|
Tue, 27 Dec 2022
Closure of Trading Window Pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 as amended & Companys Code of Internal Procedures and Conduct for Regulating Monitoring and Reporting of Trading in its securities the Trading Window for dealing in the equity shares of the Company will be closed for all Insiders Designated Persons and their immediate relatives from 1st January 2023 up to the expiry of 48 hours post the date of declaration of the Unaudited Financial Results for the quarter ended 31st December 2022. |
|
Tue, 15 Nov 2022
Announcement under Regulation 30 (LODR)-Investor Presentation Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith Investor Presentation for Q2 FY 2022-23 of the Company. |
| Tue, 31 Jan 2023 |
Opening at Low
|
Close Within 52 Week High Zone
|
High Increase in 3 Months
|
High Increase in 6 Months
|
High Increase in 1 Year
|
Equities
M.F.
Sectors